Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDF NASDAQ:ERAS NASDAQ:ESPR NASDAQ:IVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$2.12+3.7%$2.60$1.90▼$5.64$141.38M1.281.37 million shs238,147 shsERASErasca$1.87+5.4%$1.58$1.01▼$3.31$537.56M1.081.34 million shs118,373 shsESPREsperion Therapeutics$2.49+0.3%$2.03$0.69▼$3.94$501.03M0.895.01 million shs1.04 million shsIVAInventiva$5.59-1.4%$4.46$1.53▼$6.50$534.93M0.6925,144 shs15,022 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology-1.45%+2.00%-12.07%-34.19%-20.93%ERASErasca-0.56%+3.51%+10.63%+28.26%-31.79%ESPREsperion Therapeutics-1.20%-10.47%+14.29%+145.54%+52.15%IVAInventiva-5.81%+6.58%+26.85%+84.69%+158.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$2.12+3.7%$2.60$1.90▼$5.64$141.38M1.281.37 million shs238,147 shsERASErasca$1.87+5.4%$1.58$1.01▼$3.31$537.56M1.081.34 million shs118,373 shsESPREsperion Therapeutics$2.49+0.3%$2.03$0.69▼$3.94$501.03M0.895.01 million shs1.04 million shsIVAInventiva$5.59-1.4%$4.46$1.53▼$6.50$534.93M0.6925,144 shs15,022 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology-1.45%+2.00%-12.07%-34.19%-20.93%ERASErasca-0.56%+3.51%+10.63%+28.26%-31.79%ESPREsperion Therapeutics-1.20%-10.47%+14.29%+145.54%+52.15%IVAInventiva-5.81%+6.58%+26.85%+84.69%+158.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 2.80Moderate Buy$10.63402.36% UpsideERASErasca 2.57Moderate Buy$3.7199.16% UpsideESPREsperion Therapeutics 2.80Moderate Buy$7.00181.46% UpsideIVAInventiva 2.83Moderate Buy$14.83165.35% UpsideCurrent Analyst Ratings BreakdownLatest CRDF, IVA, ESPR, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.009/3/2025ERASErascaBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$4.00 ➝ $1.009/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/18/2025ERASErascaMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.00 ➝ $2.008/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $10.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$3.50(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$680K206.93N/AN/A$1.86 per share1.14ERASErascaN/AN/AN/AN/A$1.50 per shareN/AESPREsperion Therapeutics$332.31M1.51$0.02 per share104.47($1.97) per share-1.26IVAInventiva$9.95M53.74N/AN/A($1.21) per share-4.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)ERASErasca-$161.65M-$0.45N/AN/AN/AN/A-31.19%-26.34%11/11/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/A56.38-35.84%-0.91%-28.41%11/6/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)Latest CRDF, IVA, ESPR, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A8/12/2025Q2 2025ERASErasca-$0.12-$0.12N/A-$0.12N/AN/A8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 million7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A4.424.42ERASErascaN/A11.0311.04ESPREsperion TherapeuticsN/A1.150.76IVAInventivaN/A0.920.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%ERASErasca67.78%ESPREsperion Therapeutics47.39%IVAInventiva19.06%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%ERASErasca14.40%ESPREsperion Therapeutics1.70%IVAInventiva32.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableERASErasca120283.67 million242.82 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableCRDF, IVA, ESPR, and ERAS HeadlinesRecent News About These CompaniesInventiva (NASDAQ:IVA) Shares Gap Down - Time to Sell?September 23 at 1:51 PM | marketbeat.comInventiva (IVA) Expected to Announce Quarterly Earnings on ThursdaySeptember 23 at 2:05 AM | americanbankingnews.comInventiva (NASDAQ:IVA) Sees Large Volume Increase - Here's What HappenedSeptember 22 at 3:08 PM | marketbeat.comInventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 21 at 4:21 AM | americanbankingnews.comInventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 21 at 4:11 AM | marketbeat.comInventiva positioned as next acquisition target, says H.C. WainwrightSeptember 18, 2025 | msn.comInventiva (IVA) to Release Quarterly Earnings on ThursdaySeptember 18, 2025 | marketbeat.comInventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest UpdateSeptember 16, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Shares Gap Down - What's Next?September 14, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Shares Gap Up - Time to Buy?September 12, 2025 | marketbeat.comAnalysts Offer Predictions for Inventiva FY2025 EarningsSeptember 7, 2025 | marketbeat.comInventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Up 188.0% in AugustSeptember 6, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Shares Gap Up Following Analyst UpgradeSeptember 5, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Receives Buy Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comInventiva to Participate in Upcoming September Investor ConferencesSeptember 4, 2025 | globenewswire.comInventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume After Analyst UpgradeSeptember 4, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Given New $13.00 Price Target at GuggenheimSeptember 4, 2025 | marketbeat.comInventiva assumed with a Buy at H.C. WainwrightSeptember 4, 2025 | msn.comInventiva (NASDAQ:IVA) Stock Rating Upgraded by Piper SandlerAugust 31, 2025 | marketbeat.comInventiva (NASDAQ:IVA) Hits New 12-Month High - What's Next?August 29, 2025 | marketbeat.comHow Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%August 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025CRDF, IVA, ESPR, and ERAS Company DescriptionsCardiff Oncology NASDAQ:CRDF$2.12 +0.08 (+3.68%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Erasca NASDAQ:ERAS$1.86 +0.10 (+5.37%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Esperion Therapeutics NASDAQ:ESPR$2.49 +0.01 (+0.28%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Inventiva NASDAQ:IVA$5.59 -0.08 (-1.41%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
